Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics and pharmacodynamics of a new proton pump inhibitor, Ilaprazole

H Cho, MK Choi, DY Cho, CW Yeo… - The Journal of …, 2012 - Wiley Online Library
It is well known that the CYP2C19 genetic polymorphism influences the pharmacokinetics
and pharmacodynamics of proton pump inhibitors (PPIs), but no report has addressed the …
被引用次数：49 相关文章

Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.

H Cho, MK Choi, DY Cho, CW Yeo… - Journal of Clinical …, 2011 - europepmc.org
A comment on this article appears in" Impact of the CYP2C19* 17 polymorphism on the
pharmacokinetics and pharmacodynamics of proton pump inhibitors." J Clin Pharmacol …

Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole

H Cho, MK Choi, DY Cho, CW Yeo… - Journal of clinical …, 2012 - pubmed.ncbi.nlm.nih.gov
It is well known that the CYP2C19 genetic polymorphism influences the pharmacokinetics
and pharmacodynamics of proton pump inhibitors (PPIs), but no report has addressed the …

Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole

H Cho, MK Choi, DY Cho, CW Yeo… - Journal of Clinical …, 2012 - hero.epa.gov
It is well known that the CYP2C19 genetic polymorphism influences the pharmacokinetics
and pharmacodynamics of proton pump inhibitors (PPIs), but no report has addressed the …